Compare Stocks: CGTX, NLTX, AKBA, and SNDL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$1.32 -2.2%	$1.15	$0.82 ▼ $3.79	$362.15M	0.23	2.98 million shs	2.06 million shs
CGTX Cognition Therapeutics	$0.89 -2.9%	$1.15	$0.55 ▼ $3.83	$81.98M	1.75	1.03 million shs	403,630 shs
NLTX Neoleukin Therapeutics	$33.60 -0.2%	$32.29	$2.03 ▼ $14.36	$315.77M	1.11	50,104 shs	93,078 shs
SNDL SNDL	$1.23 -1.6%	$1.36	$1.17 ▼ $2.89	$321.75M	0.92	1.74 million shs	1.87 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.22%	+8.20%	+9.09%	-5.71%	-63.93%
CGTX Cognition Therapeutics	-2.88%	-3.25%	-21.27%	-30.50%	+42.98%
NLTX Neoleukin Therapeutics	-0.18%	-5.54%	+6.84%	+25.14%	+54.98%
SNDL SNDL	-1.60%	-1.20%	-10.22%	-12.77%	-14.58%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$1.32 -2.2%	$1.15	$0.82 ▼ $3.79	$362.15M	0.23	2.98 million shs	2.06 million shs
CGTX Cognition Therapeutics	$0.89 -2.9%	$1.15	$0.55 ▼ $3.83	$81.98M	1.75	1.03 million shs	403,630 shs
NLTX Neoleukin Therapeutics	$33.60 -0.2%	$32.29	$2.03 ▼ $14.36	$315.77M	1.11	50,104 shs	93,078 shs
SNDL SNDL	$1.23 -1.6%	$1.36	$1.17 ▼ $2.89	$321.75M	0.92	1.74 million shs	1.87 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.22%	+8.20%	+9.09%	-5.71%	-63.93%
CGTX Cognition Therapeutics	-2.88%	-3.25%	-21.27%	-30.50%	+42.98%
NLTX Neoleukin Therapeutics	-0.18%	-5.54%	+6.84%	+25.14%	+54.98%
SNDL SNDL	-1.60%	-1.20%	-10.22%	-12.77%	-14.58%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.40	Hold	$4.67	253.54% Upside
CGTX Cognition Therapeutics	2.50	Moderate Buy	$3.33	274.70% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
SNDL SNDL	2.00	Hold	$5.00	306.50% Upside

Current Analyst Ratings Breakdown

Latest CGTX, NLTX, AKBA, and SNDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2026	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/1/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
6/24/2026	CGTX Cognition Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/22/2026	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
6/11/2026	SNDL SNDL	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/28/2026	SNDL SNDL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/6/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/6/2026	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.50	N/A	N/A	$0.12 per share	11.00
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.39 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
SNDL SNDL	$677.32M	0.47	$0.11 per share	11.10	$2.98 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.08	N/A	N/A	N/A	-8.83%	-62.72%	-5.66%	8/5/2026 (Estimated)
CGTX Cognition Therapeutics	-$23.49M	-$0.24	N/A	N/A	N/A	N/A	-72.68%	-53.07%	8/6/2026 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	N/A	N/A	N/A	-37.22%	-30.91%	N/A
SNDL SNDL	-$11.29M	-$0.06	N/A	N/A	N/A	-2.36%	-2.01%	-1.67%	N/A

Latest CGTX, NLTX, AKBA, and SNDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGTX Cognition Therapeutics	-$0.06	N/A	N/A	N/A	$5.00 million	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.03	N/A	N/A	N/A	$48.85 million	N/A
7/28/2026	Q2 2026	SNDL SNDL	-$0.0035	-$0.02	-$0.0165	-$0.02	$166.26 million	$165.94 million
5/7/2026	Q1 2026	AKBA Akebia Therapeutics	-$0.01	-$0.03	-$0.02	-$0.03	$51.67 million	$53.54 million
5/7/2026	Q1 2026	CGTX Cognition Therapeutics	-$0.06	-$0.05	+$0.01	-$0.05	$4.40 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.33	1.40	1.33
CGTX Cognition Therapeutics	N/A	5.92	5.92
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
SNDL SNDL	0.12	4.76	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CGTX Cognition Therapeutics	43.35%
NLTX Neoleukin Therapeutics	52.37%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
CGTX Cognition Therapeutics	11.11%
NLTX Neoleukin Therapeutics	1.58%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	268.26 million	256.72 million	Optionable
CGTX Cognition Therapeutics	20	89.50 million	79.56 million	Not Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
SNDL SNDL	2,751	257.40 million	N/A	Optionable

CGTX, NLTX, AKBA, and SNDL Headlines

Recent News About These Companies

SNDL (NASDAQ:SNDL) Stock Rating Lowered by Wall Street Zen

August 1 at 1:12 AM | americanbankingnews.com

SNDL (NASDAQ:SNDL) Downgraded by Wall Street Zen to "Sell"

August 1 at 1:11 AM | marketbeat.com

Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release?

July 31 at 9:40 AM | finance.yahoo.com

Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release?

July 31 at 9:11 AM | zacks.com

SNDL Inc. Hits 52-Week Low On Weaker Q2 2026 Earnings

July 30 at 5:51 AM | seekingalpha.com

SNDL Inc. (SNDL) Q2 2026 Earnings Call Transcript

July 29 at 10:14 AM | seekingalpha.com

SNDL Shares Slide as Liquor, Cannabis Segments Drag Revenue

July 29 at 5:13 AM | marketwatch.com

SNDL completes Parallel asset acquisition, expands US medical cannabis footprint

July 28, 2026 | msn.com

Is SNDL (NASDAQ:SNDL) Stock One to Watch as Investors Reassess Medical Cannabis Consolidation and U.S. Market Positioning?

July 28, 2026 | kalkinemedia.comK

SNDL drops after second consecutive topline contraction in Q2

July 28, 2026 | seekingalpha.com

SNDL Inc (SNDL) Q2 2026 Earnings Call Highlights: Strategic Moves Amid Market Challenges

July 28, 2026 | finance.yahoo.com

SNDL Inc. (SNDL) Reports Q2 Loss, Lags Revenue Estimates

July 28, 2026 | finance.yahoo.com

SNDL Q2 Earnings Call Highlights

July 28, 2026 | marketbeat.com

SNDL Inc. (SNDL) Reports Q2 Loss, Lags Revenue Estimates

July 28, 2026 | zacks.com

SNDL (NASDAQ:SNDL) Announces Quarterly Earnings Results

July 28, 2026 | marketbeat.com

SNDL Reports Second Quarter 2026 Financial and Operational Results

July 28, 2026 | finance.yahoo.com

SNDL Reports Second Quarter 2026 Financial and Operational Results

July 28, 2026 | globenewswire.com

SNDL Files July Form 6-K With Q2 2026 Interim Financials

July 28, 2026 | tipranks.com

Can SNDL Inc (NASDAQ:SNDL) Stand Apart As Its Quarterly Results Land Tomorrow?

July 28, 2026 | kalkinemedia.comK

SNDL Inc.: SNDL Announces Completion of Parallel Asset Acquisition and Positions for Nasdaq-Consolidated U.S. Medical Cannabis Operations

July 27, 2026 | finanznachrichten.de

SNDL (NASDAQ:SNDL) climbs into view as low-priced names stir this week

July 27, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, NLTX, AKBA, and SNDL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$1.32 -0.03 (-2.22%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.33 +0.01 (+0.76%)

As of 07/31/2026 07:43 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Cognition Therapeutics NASDAQ:CGTX

$0.89 -0.03 (-2.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.91 +0.02 (+2.18%)

As of 07/31/2026 07:59 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Neoleukin Therapeutics NASDAQ:NLTX

$33.60 -0.06 (-0.18%)

As of 07/30/2026

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

SNDL NASDAQ:SNDL

$1.23 -0.02 (-1.60%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.23 0.00 (-0.41%)

As of 07/31/2026 07:59 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGTX, NLTX, AKBA, and SNDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGTX, NLTX, AKBA, and SNDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGTX, NLTX, AKBA, and SNDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, NLTX, AKBA, and SNDL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Cognition Therapeutics NASDAQ:CGTX

Neoleukin Therapeutics NASDAQ:NLTX

SNDL NASDAQ:SNDL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGTX, NLTX, AKBA, and SNDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGTX, NLTX, AKBA, and SNDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGTX, NLTX, AKBA, and SNDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, NLTX, AKBA, and SNDL Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Cognition Therapeutics NASDAQ:CGTX

Neoleukin Therapeutics NASDAQ:NLTX

SNDL NASDAQ:SNDL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools